APA (7th ed.) Citation

JF, W., & J, C. (2026). The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy. BMC cancer, 26(1), . https://doi.org/10.1186/s12885-026-15673-4

Chicago Style (17th ed.) Citation

JF, Wang, and Cheng J. "The Prognostic Value of Maintaining Minimal Residual Disease Status in Patients with Acute Myeloid Leukaemia Receiving Azacitidine-based Therapy." BMC Cancer 26, no. 1 (2026). https://doi.org/10.1186/s12885-026-15673-4.

MLA (9th ed.) Citation

JF, Wang, and Cheng J. "The Prognostic Value of Maintaining Minimal Residual Disease Status in Patients with Acute Myeloid Leukaemia Receiving Azacitidine-based Therapy." BMC Cancer, vol. 26, no. 1, 2026, https://doi.org/10.1186/s12885-026-15673-4.